[1] We have previously shown that the beta-adrenergic/5-HT1 receptor partial agonist (-)-pindolol (2.0-32.0 micromol kg(-1)) enhances the increase in forward locomotion in rats produced by the 5-HT2 receptor agonist DOI (0.7 micromol kg(-1)) via net activation of post-synaptic 5-HT2 receptors. [2] It was found that neither the 5-HT1A receptor agonist and partial agonist, (+/-) 8-OH-DPAT (0.2-2.4 micromol kg(-1)) and (S)-(-)-UH-301, respectively, nor the 5-HT1A receptor antagonist WAY-100635 (0.09-1.5 micromol kg(-1)), substituted for (-)-pindolol in this in vivo behavioral model. [3] This also applies to the 5-HT1B receptor agonist and antagonist anpirtoline (0.3-4.0 micromol kg(-1)) and isamoltane (1.0-64.0 micromol kg(-1)), respectively. Neither of these compounds mimicked (-)-pindolol in its interactions with DOI. [4] The (-)-pindolol/DOI-induced increase in forward locomotion could be antagonized by the beta1 adrenoceptor antagonist betaxolol (24 micromol kg(-1)). [5] It is suggested that the intrinsic efficacy of (-)-pindolol at beta-adrenoceptors is an important aspect of its in vivo pharmacodynamic profile.

译文

[1] 我们以前已经表明,β-肾上腺素能/5-HT1受体部分激动剂 (-)-品多洛尔 (2.0-32.0微摩尔千克 (-1)) 通过净激活增强由5-HT2受体激动剂DOI (0.7微摩尔千克 (-1)) 产生的大鼠正向运动的增加突触后5-HT2受体。[2] 发现5-HT1A受体激动剂和部分激动剂 (+/-) 8-OH-DPAT (0.2-2.4 micromol kg(-1)) 和 (S)-(-)-UH-301分别,在该体内行为模型中,也没有用5-HT1A受体拮抗剂WAY-100635 (0.09-1.5 micromol kg(-1)) 代替 (-)-pindolol。[3] 这也分别适用于5-HT1B受体激动剂和拮抗剂anpirtoline (0.3-4.0 micromol kg(-1)) 和isamoltane (1.0-64.0 micromol kg(-1))。这两种化合物在与DOI的相互作用中都没有模仿 (-)-pindolol。[4] (-)-pindolol/DOI诱导的向前运动的增加可以被 β1肾上腺素受体拮抗剂betaxolol (24 micromol kg(-1)) 拮抗。[5] 建议 (-)-pindolol对 β-肾上腺素受体的内在功效是其体内药效学特征的重要方面。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录